TIAA CREF Investment Management LLC cut its stake in Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 9.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 74,402 shares of the specialty pharmaceutical company’s stock after selling 7,626 shares during the quarter. TIAA CREF Investment Management LLC owned 0.23% of Flexion Therapeutics worth $1,504,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Fiduciary Trust Co. purchased a new stake in shares of Flexion Therapeutics in the second quarter worth approximately $101,000. IFP Advisors Inc raised its stake in shares of Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares during the last quarter. BB&T Securities LLC purchased a new stake in shares of Flexion Therapeutics in the second quarter worth approximately $289,000. Janney Montgomery Scott LLC raised its stake in shares of Flexion Therapeutics by 32.4% in the second quarter. Janney Montgomery Scott LLC now owns 17,970 shares of the specialty pharmaceutical company’s stock worth $363,000 after purchasing an additional 4,395 shares during the last quarter. Finally, Monarch Partners Asset Management LLC raised its stake in shares of Flexion Therapeutics by 86.0% in the second quarter. Monarch Partners Asset Management LLC now owns 19,310 shares of the specialty pharmaceutical company’s stock worth $390,000 after purchasing an additional 8,930 shares during the last quarter. 72.04% of the stock is owned by hedge funds and other institutional investors.

Flexion Therapeutics, Inc. (NASDAQ FLXN) opened at $23.25 on Monday. The company has a debt-to-equity ratio of 0.74, a current ratio of 18.29 and a quick ratio of 18.29.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). research analysts forecast that Flexion Therapeutics, Inc. will post -3.71 EPS for the current fiscal year.

Several analysts have recently commented on FLXN shares. Wells Fargo & Company set a $39.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 30th. Northland Securities started coverage on Flexion Therapeutics in a research note on Thursday, August 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Zacks Investment Research downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Needham & Company LLC increased their price objective on Flexion Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. Finally, Janney Montgomery Scott reissued a “buy” rating and issued a $35.00 price objective (up from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Flexion Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $88.50.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-has-1-50-million-stake-in-flexion-therapeutics-inc-flxn/1682065.html.

In other Flexion Therapeutics news, insider Yamo Deniz bought 1,375 shares of Flexion Therapeutics stock in a transaction dated Thursday, August 31st. The stock was bought at an average cost of $25.40 per share, with a total value of $34,925.00. Following the completion of the acquisition, the insider now directly owns 5,000 shares in the company, valued at approximately $127,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders bought 5,375 shares of company stock valued at $131,575. 15.98% of the stock is currently owned by corporate insiders.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics, Inc. (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.